A realistic benefit of ICB is their ability to elicit prolonged remissions in certain cancers, with patients responding to PD-1/PD-L1 inhibitors often experiencing stable disease for extended periods, in stark contrast to the typically transient and recurrent effects of chemotherapy. Here, CD274 is linked to cancer.